263 related articles for article (PubMed ID: 32660222)
21. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
22. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
23. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
24. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
25. Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR.
Luo XL; Deng CC; Su XD; Wang F; Chen Z; Wu XP; Liang SB; Liu JH; Fu LW
Cancer Res; 2018 Jul; 78(13):3532-3543. PubMed ID: 29735544
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
28. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
29. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
30. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
Cao L; Wan Q; Li F; Tang CE
BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
[TBL] [Abstract][Full Text] [Related]
31. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
32. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
33. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
34. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
35. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
36. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
37. IGF1R-α6 integrin-S100A4 network governs the organ-specific metastasis of chemoresistant epithelial ovarian cancer cells.
Deo AN; Thorat R; Dhadve AC; De A; Rekhi B; Ray P
Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166282. PubMed ID: 34600083
[TBL] [Abstract][Full Text] [Related]
38. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
39. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
40. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
